Afatinib CAS 439081-18-2 Bohloeki >99.5% (HPLC) Factory
Ruifu Chemical Supply Intermediates of Afatinib
Afatinib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
(Dimethylamino)acetaldehyde Diethyl Acetal CAS 3616-56-6
trans-4-Dimethylaminocrotonic Acid Hydrochloride CAS 848133-35-7
Diethylphosphonoacetic Acid CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4 (1H)-e le 'ngoe CAS 162012-69-3
7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S)-N4-(3-Chloro-4-Fluorophenyl)-7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-DiamineCAS 314771-76-1
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-AmineCAS 314771-88-5
Lebitso la Lik'hemik'hale | Afatinib |
Litlhaloso tse tšoanang | BIBW2992;BIBW-2992;BIBW2992 Free Base;Tomtovok;(S,E)-N-(4-(3-Chloro-4-Fluorophenylamino)-7-(Tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(Dimethylamino)but-2-Enamide |
Nomoro ea CAS | 439081-18-2 |
Nomoro ea KAtse | RF-PI2033 |
Boemo ba Setoko | Ka Setokong, Sekhahla sa Tlhahiso Ho fihlela ho Lithane |
Foromo ea limolek'hule | C24H25ClFN5O3 |
Boima ba Molek'hule | 485.94 |
Solubility | E qhibiliha ka DMSO |
Botenya | 1.380 |
Brand | Ruifu Chemical |
Ntho | Litlhaloso |
Ponahalo | Phofo e Ntle-Tšweu |
Boitsebiso | HPLC, NMR |
Mokhoa oa Bohloeki / Analysis | >99.5% (HPLC) |
Melting Point | 100.0 ~ 102.0℃ |
Tahlehelo ka ho Omisa | <0.50% |
Masalla a ho Ignition | <0.20% |
Litšila ka Kakaretso | <0.50% |
Litšepe tse boima | ≤20ppm |
Sekhahla sa NMR | E Ikamahanya le Sebopeho |
Tekanyetso ea Teko | Maemo a Khoebo |
Shelf Life | Likhoeli tse 24 Haeba li Behiloe Hantle |
Tšebeliso | API;Afatinib;Afatinib Dimaleate;NSCLC |
Sephutheloana: Botlolo, Aluminium foil bag, 25kg/Cardboard Drum, kapa ho ea ka tlhokahalo ea moreki.
Boemo ba polokelo:Boloka ka lijaneng tse koetsoeng sebakeng se phodileng le se omileng;Sireletsa leseli le mongobo
Afatinib, eo hape e tsejoang e le BIW-2992, (CAS: 439081-18-2) ke moloko oa bobeli o matla le o ke keng oa fetoloa oa inhibitor ea epidermal growth factor receptor (EGFR) le human epidermal growth factor receptor 2 (HER2) tyrosine kinase, e ntlafalitsoeng ke Boehringer Ingelheim, Jeremane.E khona ho thibela mosebetsi oa tyrosine kinase ka mokhoa o ke keng oa fetoloa ka ho itšoara ka Michael le sehlopha sa thiol sa cysteine e boemong ba 797 ba EGFR.Ka la 12 Phupu, 2013, e ile ea fetoha setlhare se secha bakeng sa mofetše o monyane oa lisele tsa matšoafo o amohetsoeng ke US FDA tlasa lebitso la khoebo la Gilotrif.Setlhare sena ke letlapa.E sebelisoa bakeng sa kalafo ea bakuli ba fumanoeng ba e-na le mofetše oa metastatic o seng o nyane oa sele ea matšoafo (NSCLC) ka tahlehelo ea phetoho ea 19th exon kapa L858R ho 21th exon ea tumor epidermal growth factor receptor (EGFR) e netefalitsoeng ho sebelisoa kit e amohetsoeng. ka FDA.Setlhare sena se boetse se sebetsa hantle kalafong ea bakuli ba nang le HER2 ba nang le mofetše oa matsoele o tsoetseng pele.Afatinib ke ea sehlopha sa lithethefatsi tse tsejoang e le tyrosine kinase inhibitors.Tyrosine kinase inhibitors e etselitsoe ho thibela ketso ea enzyme e itseng e bitsoang tyrosine kinase.Enzyme ena e bapala karolo e kholo ts'ebetsong ea lisele, 'me e sebetsa ka mafolofolo ho holiseng le ho tsoela pele ha hlahala.Afatinib e sebetsa ho thibela tšebetso ea mefuta e 'meli ea tyrosine kinases: epidermal growth factor receptor (EGFR) le Her2, tse "hlahisoang ho feta" ke mefuta e mengata ea kankere.Ka ho thibela tšebetso ea tyrosine kinase tsena, Afatinib e ka thibela lisele tsa mofetše ho arohana le ho hola.